Arsena H, Munir SM. Efficacy and Safety of Adding Antiangiogenic Therapy to EGFR-Tyrosine Kinase Inhibitors versus EGFR-Tyrosine Kinase Inhibitor Monotherapy in EGFR-Mutant Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Bioscmed [Internet]. 2026Jun.12 [cited 2026Jun.16];10(7):2624-36. Available from: https://www.bioscmed.com/index.php/bsm/article/view/1638